首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 製藥企業 > 全球的藥品市場趨勢： 2006 年 - 2010 年
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

全球的藥品市場趨勢： 2006 年 - 2010 年

Pharmaceutical Market Trends, 2006-2010

出版商 Urch Publishing, Ltd.
出版日期 2006年06月 商品編碼 41779
內容資訊 英文 172 pages
價格
US $ 1990 PDF by E-mail (Single User License)
US $ 2100 Hard Copy


全球的藥品市場趨勢： 2006 年 - 2010 年 是由出版商Urch Publishing, Ltd.在2006年06月所出版的。 這份英文市場調查報告書包含172 pages 價格從美金1990起跳。

簡介

全球的藥品市場預計在 2010 年前將達到 8420 億美元的規模。其數字意味著於該市場今後 5 年內每年將以 CAGR 6.9% 的速度成長。

因提供針對藥品產業經營層的資訊而獲高度評價的英國市調公司 Urch Publishing, Ltd. （總公司：倫敦），針對 2006 年至 2010 年間全球藥品市場的發展趨勢進行詳盡的調查分析，並出版報告書 "Pharmaceutical Market Trends, 2006-2010" 。

本報告書內容包括：美國、歐洲、日本等主要市場的趨勢分析、心臟血管、中樞神經、營養／代謝等主要治療領域別市場的詳盡分析、主要產品和主要企業的資料以及今後發展預測等。內容綱要摘記如下：

摘要

第1章 序章

  • 全球的藥品市場
  • 本書之簡介

第2章 全球的主要市場

  • 主要的藥品市場
  • 美國
  • 歐洲
  • 日本

第3章 主要治療領域別市場

  • 主要治療領域
  • 心臟血管
  • 中樞神經
  • 營養／代謝
  • 呼吸器官
  • 抗傳染
  • 肌肉骨骼
  • 抑制細胞增殖

第4章 主要產品

  • 主要產品
    • Lipitor ( Atorvastatin )
    • Plavix ( Clopidogrel )
    • Advair ／ Seretide ( Fluticasone; Salmeterol )
    • Norvasc ( Amlodipine )
    • Nexium ( Esomeprazole )
    • Zocor ( Simvastatin )
    • Zyprexa ( Olanzapine )
    • Prevacid ( Lansoprazole )
    • Diovan/ Co-Diovan ( Valsartan ／ hydrochlorothiazide )
    • Enbrel ( Etanercept )
  • 熱門產品趨勢
    • 產品類型別
    • 治療領域別
    • 企業別

第5章 主要企業

  • 主要藥品企業
    • 財務狀況
    • 據點
  • 10 大企業
    • 財務狀況
    • 價值驅動因素
  • 主要藥品企業
    • Pfizer
    • Sanofi-Aventis
    • GlaxoSmithKline
    • AstraZeneca
    • Johnson and Johnson
    • Roche
    • Merck & Co
    • Novartis
    • Wyeth
    • Bristol-Myers Squibb

第6章 主要趨勢與機會

  • 全球市場預測
  • 美國市場
  • 主要治療領域的預測
  • 主要產品的預測
  • 主要企業的預測

附錄

圖表

目錄

Abstract

Pharmaceutical Market Trends, 2006: Key market forecasts & growth opportunities presents a detailed trend analysis of the global pharmaceutical market as at the end of 2005 and forecasts until 2010. The 170 page report presents a series of market forecasts and growth opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting.

The data and analysis contained within the report are comprehensive, consistent and up-to-date in order to provide a single-point reference for understanding key pharmaceutical market trends in 2006.

Headline Findings

  • The global pharmaceutical market is forecast to grow to US$842 billion in 2010, an equivalent CAGR of 6.9% over the next five years.
  • Strong growth in the 10 European markets that joined the European Union in 2004 will help to boost European sales over the next five years.
  • Of the leading product classes in 2005, cytostatics and angiotensin-II inhibitors generated the greatest year-on-year growth.
  • There were a total of 16 new blockbuster drugs in 2005, generating combined sales of US$18.1 billion.
  • Total pharmaceutical sales from the top 10 companies accounted for more than 40% of the total market.

Table of Contents

Summary

  • Introduction
  • Key global markets
  • Key therapeutic markets
  • Key products
  • Key companies
  • Key trends and opportunities

Chapter 1. Introduction

  • Global pharmaceutical market
  • Report overview
    • Methodology
    • Sources
    • Structure

Chapter 2. Key global markets

  • Key pharmaceutical markets
  • US pharmaceutical market
    • US purchasing channels
    • US retail drug market
    • US therapy areas
    • US market leaders
  • European pharmaceutical market
    • European retail drug market
    • European therapy areas
  • Japanese pharmaceutical market
    • Japanese therapy areas

Chapter 3. Key therapeutic markets

  • Key therapy areas
    • Retail drug therapy areas
  • Cardiovascular therapy area
    • Cardiovascular markets
    • Cardiovascular blockbusters
  • Central nervous system therapy area
    • Central nervous system markets
    • Central nervous system blockbusters
  • Alimentary/ metabolism therapy area
    • Alimentary/ metabolism markets
    • Alimentary/ metabolism blockbusters
  • Respiratory therapy area
    • Respiratory markets
    • Respiratory blockbusters
  • Anti-infectives therapy area
    • Anti-infectives markets
    • Anti-infectives blockbusters
  • Musculo-skeletal therapy area
    • Musculo-skeletal markets
    • Musculo-skeletal blockbusters
  • Cytostatics therapy area
    • Cytostatics markets
    • Cytostatics blockbusters

Chapter 4. Key products

  • Leading products
    • Lipitor (atorvastatin)
    • Plavix (clopidogrel)
    • Advair/ Seretide (fluticasone; salmeterol)
    • Norvasc (amlodipine)
    • Nexium (esomeprazole)
    • Zocor (simvastatin)
    • Zyprexa (olanzapine)
    • Prevacid (lansoprazole)
    • Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide)
    • Enbrel (etanercept)
  • Blockbuster trends
    • Blockbusters by drug type
    • Blockbusters by therapy area
    • Blockbusters by company

Chapter 5. Key companies

  • Major pharmaceutical companies
    • Major company financials
    • Major company locations
  • Top 10 pharmaceutical companies
    • Top 10 company financials
    • Top 10 company value drivers
  • Leading pharmaceutical companies
    • Pfizer
    • Sanofi-Aventis
    • GlaxoSmithKline
    • AstraZeneca
    • Johnson and Johnson
    • Roche
    • Merck & Co
    • Novartis
    • Wyeth
    • Bristol-Myers Squibb

Chapter 6. Key trends and opportunities

  • Global market forecasts
  • The US market
    • The European market
    • The Japanese market
    • Other markets
  • Key therapy area forecasts
    • Cardiovascular market
    • Central nervous system market
    • Alimentary/ metabolism market
    • Anti-infectives market
    • Respiratory market
  • Key product forecasts
    • Lipitor (atorvastatin)
    • Plavix (clopidogrel)
    • Advair/ Seretide (fluticasone; salmeterol)
    • Norvasc (amlodipine)
    • Nexium (esomeprazole)
    • Zocor (simvastatin)
    • Zyprexa (olanzapine)
    • Prevacid (lansoprazole)
    • Diovan/ Co-Diovan (valsartan; hydrochlorothiazide)
    • Enbrel (etanercept)
  • Key company forecasts
    • Pfizer
    • Sanofi-Aventis
    • GlaxoSmithKline
    • AstraZeneca
    • Johnson and Johnson
    • Roche
    • Merck & Co
    • Novartis
    • Wyeth
    • Bristol-Myers Squibb

Appendix

  • Proprietary data sources
    • Product Trends Database
  • Company Trends Database
  • Top 100 pharmaceutical products
  • Top 64 pharmaceutical companies

List of Figures

  • Figure 1: Global pharmaceutical market, 1999-2005
  • Figure 2: Report structure
  • Figure 3: Global pharmaceutical market share by region, 2005
  • Figure 4: Global pharmaceutical market by region, 2003-2005
  • Figure 5: US pharmaceutical market, 2003-2005
  • Figure 6: US pharmaceutical market share by purchasing channel,
  • Figure 7: US pharmaceutical market by purchasing channel, 2003-
  • Figure 8: US retail pharmaceutical market, 2003-2005
  • Figure 9: US retail pharmaceutical market share by therapy area, 2005
  • Figure 10: US retail pharmaceutical market by therapy area, 2003-2005
  • Figure 11: Top 10 products by US pharmaceutical sales, 2005
  • Figure 12: Top 10 companies by US pharmaceutical sales,
  • Figure 13: Top 10 companies by share of US pharmaceutical sales,
  • Figure 14: European pharmaceutical market, 2003-2005
  • Figure 15: European pharmaceutical market share by country, 2005
  • Figure 16: European top 5 retail pharmaceutical market, 2003-2005
  • Figure 17: European top 5 retail pharmaceutical market share by country, 2005
  • Figure 18: European top 5 retail pharmaceutical market by country, 2003-2005
  • Figure 19: European top 5 retail pharmaceutical market share by therapy area, 2005
  • Figure 20: European top 5 retail pharmaceutical market by therapy area, 2003-2005
  • Figure 21: Japanese pharmaceutical market, 2003-2005
  • Figure 22: Japanese pharmaceutical market share by therapy area, 2005
  • Figure 23: Japanese pharmaceutical market by therapy area, 2003-2005
  • Figure 24: Global pharmaceutical market by therapy area, 2005
  • Figure 25: Top 10 product classes by global pharmaceutical sales, 2005
  • Figure 26: Global retail pharmaceutical market share by therapy area, 2005
  • Figure 27: Global retail pharmaceutical market by therapy area, 2003-
  • Figure 28: Cardiovascular retail pharmaceutical market, 2003-2005
  • Figure 29: Cardiovascular retail pharmaceutical market share by country, 2005
  • Figure 30: Cardiovascular retail pharmaceutical market by country, 2003-2005
  • Figure 31: Central nervous system retail pharmaceutical market, 2003-2005
  • Figure 32: Central nervous system retail pharmaceutical market share by country, 2005
  • Figure 33: Central nervous system retail pharmaceutical market by country, 2003-2005
  • Figure 34: Alimentary/ metabolism retail pharmaceutical market, 2003-2005
  • Figure 35: Alimentary/ metabolism retail pharmaceutical market share by country, 2005
  • Figure 36: Alimentary/ metabolism retail pharmaceutical market by country, 2003-2005
  • Figure 37: Respiratory retail pharmaceutical market, 2003-2005
  • Figure 38: Respiratory retail pharmaceutical market share by country, 2005
  • Figure 39: Respiratory retail pharmaceutical market by country, 2003-2005
  • Figure 40: Anti-infectives retail pharmaceutical market, 2003-2005
  • Figure 41: Anti-infectives retail pharmaceutical market share by country, 2005
  • Figure 42: Anti-infectives retail pharmaceutical market by country, 2003-2005
  • Figure 43: Musculo-skeletal retail pharmaceutical market, 2003-2005
  • Figure 44: Musculo-skeletal retail pharmaceutical market share by country, 2005
  • Figure 45: Musculo-skeletal retail pharmaceutical market by country, 2003-2005
  • Figure 46: Cytostatics retail pharmaceutical market, 2003-2005
  • Figure 47: Cytostatics retail pharmaceutical market share by country, 2005
  • Figure 48: Cytostatics retail pharmaceutical market by country, 2003-2005
  • Figure 49: Blockbuster drug sales share by drug type, 2005
  • Figure 50: Blockbuster drug sales share by lifecycle stage, 2005
  • Figure 51: Blockbuster drug sales share by therapy area, 2005
  • Figure 52: Blockbuster drug sales share by company, 2005
  • Figure 53: Major companies pharmaceutical sales, 2003-2005
  • Figure 54: Major companies revenue share allocation, 2005
  • Figure 55: Major companies revenue allocation, 2003-2005
  • Figure 56: Major companies pharmaceutical sales by location, 2005
  • Figure 57: Top 10 pharma companies pharmaceutical sales, 2003-2005
  • Figure 58: Top 10 pharma companies by global pharmaceutical sales, 2005
  • Figure 59: Top 10 biotechnology companies by global revenues, 2005
  • Figure 60: Top 10 pharma companies revenue share allocation, 2005
  • Figure 61: Top 10 pharma companies revenue allocation, 2003-2005
  • Figure 62: Key value drivers for top 10 pharma companies (income), 2005
  • Figure 63: Key value drivers for top 10 pharma companies (sales), 2005
  • Figure 64: Key value drivers for top 10 pharma companies (sales/ R&D), 2005
  • Figure 65: Pfizer therapy area sales, 2003-2005
  • Figure 66: Sanofi-Aventis blockbuster therapy area sales, 2003-2005
  • Figure 67: GlaxoSmithKline therapy area sales, 2003-2005
  • Figure 68: AstraZeneca therapy area sales, 2003-2005
  • Figure 69: Johnson and Johnson blockbuster therapy area sales, 2003-2005
  • Figure 70: Roche therapy area sales, 2003-2005
  • Figure 71: Merck & Co blockbuster therapy area sales, 2003-2005
  • Figure 72: Novartis therapy area sales, 2003-2005
  • Figure 73: Wyeth blockbuster therapy area sales, 2003-2005
  • Figure 74: Bristol-Myers Squibb therapy area sales, 2005
  • Figure 75: Global pharmaceutical market forecast, 2003-2010
  • Figure 76: Global pharmaceutical market forecast by regions, 2003-2010
  • Figure 77: Top 10 pharmaceutical drugs by forecast sales, 2010
  • Figure 78: Lipitor (atorvastatin) forecast sales, 2003-2010
  • Figure 79: Plavix (clopidogrel) forecast sales, 2003-2010
  • Figure 80: Advair/ Seretide (fluticasone; salmeterol) forecast sales, 2003-
  • Figure 81: Norvasc (amlodipine) forecast sales, 2003-2010
  • Figure 82: Nexium (esomeprazole) forecast sales, 2003-2010
  • Figure 83: Zocor (simvastatin) forecast sales, 2003-2010
  • Figure 84: Zyprexa (olanzapine) forecast sales, 2003-2010
  • Figure 85: Prevacid (lansoprazole) forecast sales, 2003-2010
  • Figure 86: Diovan/ Co-Diovan (valsartan; hydrochlorothiazide) forecast sales, 2003-2010
  • Figure 87: Enbrel (etanercept) forecast sales, 2003-2010

List Of Tables

  • Table 1: Global pharmaceutical market trends by region, 2003-2005
  • Table 2: US pharmaceutical market trends by purchasing channel, 2003-2005
  • Table 3: US retail pharmaceutical market trends by therapy area, 2003-2005
  • Table 4: Top 10 products trends by US pharmaceutical sales, 2003-2005
  • Table 5: European top 5 retail pharmaceutical market trends by country, 2003-2005
  • Table 6: European top 5 retail pharmaceutical market trends by therapy area, 2003-2005
  • Table 7: Japanese pharmaceutical market trends by therapy area, 2003-2005
  • Table 8: Top 10 product classes trends by global pharmaceutical sales, 2004-2005
  • Table 9: Global retail pharmaceutical market trends by therapy area, 2003-2005
  • Table 10: Cardiovascular retail pharmaceutical market trends by country, 2003-2005
  • Table 11: Cardiovascular blockbuster drug sales, 2003-2005
  • Table 12: Central nervous system retail pharmaceutical market trends by country, 2003-2005
  • Table 13: Central nervous system blockbuster drug sales, 2003-2005
  • Table 14: Alimentary/ metabolism retail pharmaceutical market trends by country, 2003-2005
  • Table 15: Alimentary/ metabolism blockbuster drug sales, 2003-2005
  • Table 16: Respiratory retail pharmaceutical market trends by country, 2003-2005
  • Table 17: Respiratory blockbuster drug sales, 2003-2005
  • Table 18: Anti-infectives retail pharmaceutical market trends by country, 2003-2005
  • Table 19: Anti-infectives blockbuster drug sales, 2003-2005
  • Table 20: Musculo-skeletal retail pharmaceutical market trends by country, 2003-2005
  • Table 21: Musculo-skeletal blockbuster drug sales, 2003-2005
  • Table 22: Cytostatics retail pharmaceutical market trends by country, 2003-2005
  • Table 23: Cytostatics blockbuster drug sales, 2003-2005
  • Table 24: Top 20 products by global pharmaceutical sales, 2003-2005
  • Table 25: Lipitor (atorvastatin) profile, 2005
  • Table 26: Plavix (clopidogrel) profile, 2005
  • Table 27: Advair/ Seretide (fluticasone; salmeterol) profile, 2005
  • Table 28: Norvasc (amlodipine) profile, 2005
  • Table 29: Nexium (esomeprazole) profile, 2005
  • Table 30: Zocor (simvastatin) profile, 2005
  • Table 31: Zyprexa (olanzapine) profile, 2005
  • Table 32: Prevacid (lansoprazole) profile, 2005
  • Table 33: Diovan/ Co-Diovan (valsartan/ hydrochlorothiazide) profile, 2005
  • Table 34: Enbrel (etanercept) profile, 2005
  • Table 35: Top 10 blockbuster products by global pharmaceutical sales growth, 2003-2005
  • Table 36: Top 10 blockbuster products by declining global pharmaceutical sales, 2003-2005
  • Table 37: New blockbuster products, 2003-2005
  • Table 38: Major companies revenue allocation trends, 2003-2005
  • Table 39: Top 10 pharma companies by global pharmaceutical sales, 2003-2005
  • Table 40: Top 10 biotechnology companies by global revenues, 2003-2005
  • Table 41: Top 10 pharma companies revenue allocation trends, 2003-2005
  • Table 42: Pfizer profile, 2005
  • Table 43: Pfizer blockbuster sales, 2003-2005
  • Table 44: Sanofi-Aventis profile, 2005
  • Table 45: Sanofi-Aventis blockbuster sales, 2003-2005
  • Table 46: GlaxoSmithKline profile, 2005
  • Table 47: GlaxoSmithKline blockbuster sales, 2003-2005
  • Table 48: AstraZeneca profile, 2005
  • Table 49: AstraZeneca blockbuster sales, 2003-2005
  • Table 50: Johnson and Johnson profile, 2005
  • Table 51: Johnson and Johnson blockbuster sales, 2003-2005
  • Table 52: Roche profile, 2005
  • Table 53: Roche blockbuster sales, 2003-2005
  • Table 54: Merck & Co profile, 2005
  • Table 55: Merck & Co blockbuster sales, 2003-2005
  • Table 56: Novartis profile, 2005
  • Table 57: Novartis blockbuster sales, 2003-2005
  • Table 58: Wyeth profile, 2005
  • Table 59: Wyeth blockbuster sales, 2003-2005
  • Table 60: Bristol-Myers Squibb profile, 2005
  • Table 61: Bristol-Myers Squibb blockbuster sales, 2003-2005
  • Table 62: Global pharmaceutical market forecast by regions, 2003-2010
  • Table 63: Global pharmaceutical market forecast by therapy area, 2005-2010
  • Table 64: Top 10 pharmaceutical drugs forecast, 2003-2010
  • Table 65: Top 10 pharmaceutical companies forecast, 2005-2010
  • Table 66: Top 100 products by global pharmaceutical sales, 2003-2005
  • Table 67: Top 64 companies by global pharmaceutical sales, 2003-2005
Back to Top